{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:41:39Z","timestamp":1777650099199,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["320030_163430"],"award-info":[{"award-number":["320030_163430"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.yebeh.2017.03.031","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T08:16:07Z","timestamp":1499156167000},"page":"41-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?"],"prefix":"10.1016","volume":"74","author":[{"given":"Jennifer","family":"D'Anto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlodzimierz","family":"Wnuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea O.","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Novy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.03.031_bb0005","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","article-title":"Effectiveness of first antiepileptic drug","volume":"42","author":"Kwan","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0013-9580.2004.455005.x","article-title":"The use of antiepileptic drugs\u2014principles and practice","volume":"45","author":"Sander","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","article-title":"Therapeutic drug monitoring of antiepileptic drugs by use of saliva","volume":"35","author":"Patsalos","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2010.08.002","article-title":"Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy","volume":"91","author":"Malerba","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0035","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0040","first-page":"478","article-title":"Simultaneous determination of seventeen antiepileptic compounds in serum by isocratic reversed-phase liquid chromatography","volume":"23","author":"Wnuk","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0045","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0050","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1528-1167.2011.03355.x","article-title":"Revising the \"rule of three\" for inferring seizure freedom","volume":"53","author":"Westover","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":"The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response","volume":"19","author":"Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1157.1984.tb03441.x","article-title":"Validation of the phenomenon of regression of seizure frequency in epilepsy","volume":"25","author":"Spilker","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1528-1157.1996.tb00605.x","article-title":"Concentration\u2014effect and concentration\u2014toxicity relations with lamotrigine: a prospective study","volume":"37","author":"Kilpatrick","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0070","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/sj.npp.1300831","article-title":"Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine","volume":"30","author":"Theis","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0075","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1528-1157.1988.tb03767.x","article-title":"EEG and other early predictors of epilepsy remission: a community study","volume":"29","author":"Shafer","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0080","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1528-1157.1993.tb02126.x","article-title":"Some aspects of prognosis in the epilepsies: a review","volume":"34","author":"Sander","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.03.031_bb0085","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.eplepsyres.2014.04.004","article-title":"Natural course and predictors of spontaneous seizure remission in idiopathic generalized epilepsy: 7\u201327years of follow-up","volume":"108","author":"von Podewils","year":"2014","journal-title":"Epilepsy Res"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017301014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017301014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:24:14Z","timestamp":1761503054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017301014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":17,"alternative-id":["S1525505017301014"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.03.031","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}